ASP6294 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 226 | 間質性膀胱炎（ハンナ型） | 10 |
226. 間質性膀胱炎（ハンナ型）
臨床試験数 : 145 / 薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-004138-12-BE (EUCTR) | 27/11/2017 | 19/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Spain;Belgium;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 2 | EUCTR2016-004138-12-GB (EUCTR) | 30/10/2017 | 17/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 3 | EUCTR2016-004138-12-NL (EUCTR) | 23/10/2017 | 24/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not Applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Latvia;Germany;Netherlands;United Kingdom | ||
| 4 | NCT03282318 (ClinicalTrials.gov) | September 28, 2017 | 12/9/2017 | A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome;Interstitial Cystitis | Drug: ASP6294;Drug: Placebo | Astellas Pharma Europe B.V. | NULL | Completed | 18 Years | N/A | Female | 119 | Phase 2 | Belgium;Czechia;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom |
| 5 | EUCTR2016-004138-12-PL (EUCTR) | 27/09/2017 | 19/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Belgium;Spain;Poland;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 6 | EUCTR2016-004138-12-DE (EUCTR) | 26/09/2017 | 10/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 7 | EUCTR2016-004138-12-ES (EUCTR) | 18/09/2017 | 18/09/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 8 | EUCTR2016-004138-12-HU (EUCTR) | 14/09/2017 | 12/07/2017 | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Czech Republic;Hungary;Spain;Poland;Belgium;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 9 | EUCTR2016-004138-12-CZ (EUCTR) | 30/08/2017 | 13/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | ||
| 10 | EUCTR2016-004138-12-LV (EUCTR) | 04/08/2017 | 25/07/2017 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294 | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: no | 163 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Germany;Latvia;United Kingdom |